Market Place
Sourcing Support
Incyte Seeks Monjuvi Label Expansion After Phase 3 Lymphoma Win
19 Aug 2024 //
FIERCE PHARMA
Incyte Announces Positive Results From Tafasitamab Study In Follicular Lymphoma
15 Aug 2024 //
BUSINESSWIRE
InnoCare`s Tafasitamab BLA Accepted For DLBCL Treatment In China
20 Jun 2024 //
BUSINESSWIRE
Incyte Gains Development and Commercialization Rights to Tafasitamab (Monjuvi®)
05 Feb 2024 //
BUSINESSWIRE
China’s CDE grants approval for InnoCare’s NHL therapy trial
21 Dec 2022 //
CLINICALTRIALSARENA
InnoCare Announces Approval to Conduct a Ph II Clinical Trial of Orelabrutinib
20 Dec 2022 //
BUSINESSWIRE
MorphoSys to Share New Data on Pelabresib and Monjuvi in 14 Presentations at ASH
03 Nov 2022 //
ACCESSWIRE
MorphoSys to Share New Data on Pelabresib and Monjuvi®
03 Nov 2022 //
PRESS RELEASE
MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales
21 Oct 2022 //
ACCESSWIRE
MorphoSys shows Data from L-MIND Suggesting Response to Treatment with Monjuvi
28 Sep 2022 //
BUSINESSWIRE
InnoCare Announces 1st Patient Dosed in PII Trial of Tafasitamab & Lenalidomide
08 Sep 2022 //
BUSINESSWIRE
InnoCare`s BLA for Tafasitamab in Combination with Lenalidomide got Acceptence
30 Aug 2022 //
BUSINESSWIRE
MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results
03 Aug 2022 //
BUSINESSWIRE
Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi
13 Jun 2022 //
BUSINESSWIRE
MorphoSys and Incyte Announce Additional Real-World Evidence Results RE-MIND2
11 Dec 2021 //
BUSINESSWIRE
MorphoSys, Incyte Show Additional Real-World Data from RE-MIND2 Study
11 Dec 2021 //
BUSINESSWIRE
MorphoSys AG announces Monjuvi(R) Sales for the First Nine Months
02 Nov 2021 //
MORPHOSYS
Specialised Therapeutics Enters into a New Supply and Distribution Agreement
21 Oct 2021 //
PRNEWSWIRE
Incyte`s Minjuvi (tafasitamab) Receives Approval in Europe
26 Aug 2021 //
EMA
Incyte and MorphoSys announce European Commission clearance of Minjuvi ®
26 Aug 2021 //
BUSINESSWIRE
Morphosys Us Inc`s Biological Tafasitamab-Cxix Receives Approval In US
02 Jun 2021 //
FDA
Health Canada accepts Incyte & MorphoSys’ NDS for tafasitamab in combo
13 Jan 2021 //
PHARMABIZ
Incyte and MorphoSys Announce by Health Canada of the NDA for Tafasitamab
12 Jan 2021 //
BIOSPACE
Xencor, MorphoSys and Incyte Enter into Global Development Collaboration
11 Nov 2020 //
BIOSPACE
National Comprehensive Cancer Network® Adds Monjuvi® (tafasitamab-cxix)
18 Aug 2020 //
BUSINESSWIRE
FDA hands MorphoSys and Incyte a quick OK on their potential blockbuster CAR-T
04 Aug 2020 //
ENDPTS
In a first, MorphoSys, Incyte win Monjuvi FDA nod in lymphoma
03 Aug 2020 //
FIERCE PHARMA
FDA Approves Monjuvi® (tafasitamab-cxix) in Combination With Lenalidomide
31 Jul 2020 //
BUSINESSWIRE
Xencor Earns Milestone Payment from MorphoSys for FDA Approval of Monjuvi®
31 Jul 2020 //
BUSINESSWIRE
EMA starts review of MorphoSys’ tafasitamab for lymphoma
23 May 2020 //
PMLIVE
Incyte & MorphoSys Announce the Validation of European Marketing for Tafasitamab
20 May 2020 //
BUSINESSWIRE
MorphoSys & Incyte Announce Antitrust Clearance of Global Collab for Tafasitamab
03 Mar 2020 //
YAHOO
MorphoSys Initiates Expanded Access Program for Tafasitamab in the U.S.
04 Feb 2020 //
PRESS RELEASE
MorphoSys & Incyte Sign Global Collab and License Agreement for Tafasitamab
13 Jan 2020 //
PRESS RELEASE
Morphosys CFO says tafasitamab drug sales potential above $1 billion: magazine
03 Dec 2019 //
REUTERS
Morphosys to boost size of tafasitamab drug trial on encouraging interim data
20 Nov 2019 //
REUTERS
Morphosys to boost size of tafasitamab drug trial on encouraging interim data
20 Oct 2019 //
REUTERS
Morphosys to boost size of tafasitamab drug trial on encouraging interim data
20 Oct 2019 //
REUTERS
MorphoSys to submit MAA for tafasitamab to European Medicines Agency
07 Aug 2019 //
PHARMABIZ
